Vanda Pharmaceuticals Reports Impressive Financial Gains
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has released its financial highlights for the noteworthy 2025 fiscal year. The company's full-year net product sales for Fanapt reached an impressive $117.3 million, indicating a robust 24% increase compared to the previous year.
In total, Vanda recorded a 9% bump in its total revenues, reaching $216.1 million. This growth signifies a rapidly expanding market presence and reflects the company's dedication to delivering innovative therapies to patients in need.
Operational Achievements and New Developments
A key aspect of Vanda's success stems from its flagship product, Fanapt, which enjoyed substantial growth in 2025, attributed to a 36% increase in total prescriptions. This rise in prescriptions notably includes a 149% surge in new-to-brand prescriptions, showcasing positive traction in treating schizophrenia and bipolar I disorder.
The recent FDA approval of NEREUS™ (tradipitant) marks a historic moment for the company, representing the first oral therapy for motion-induced vomiting in over four decades. This breakthrough is expected to address the needs of approximately 65-78 million adults in the United States, with an anticipated launch driving further revenues for the company.
Financial Highlights of the Fourth Quarter
In the fourth quarter of 2025, Vanda's total net product sales from Fanapt, HETLIOZ, and PONVORY reached $57.2 million, reflecting an 8% increase from the prior year's fourth quarter sales of $53.2 million. Fanapt specifically saw net product sales of $33.2 million, which is a remarkable 25% growth compared to the $26.6 million tallied in the fourth quarter of 2024.
Despite the increases in revenues, the company's operational arms faced challenges with a reported loss before income taxes amounting to $38 million in Q4 2025, compared to a loss of $6.5 million in Q4 2024. This was influenced by a significant provision for income taxes caused by recording a valuation allowance against all of Vanda's deferred tax assets.
Overview of Full Year Results
Looking back at the entire fiscal year of 2025, Vanda's financial picture remains positive. Total net product sales from Fanapt, HETLIOZ, and PONVORY culminated in $216.1 million for the full year—a 9% increase over the $198.8 million from 2024. Despite some decreases in sales of HETLIOZ and PONVORY, the overall portfolio indicates potential for continued growth.
Going into 2026, Vanda anticipates total revenues between $230 million and $260 million, reinforced by ongoing marketing efforts and the anticipated launches of NEREUS, Bysanti™ for bipolar I disorder and schizophrenia, along with further developments around the imsidolimab BLA.
Strategic Growth and Future Outlook
Vanda's initiatives to enhance brand awareness through a direct-to-consumer campaign have demonstrated efficacy, resulting in increased visibility for its products. The company plans to escalate investments in its commercial infrastructure, reinforcing its market position and fostering long-term growth.
Pivotal to this continued success is Vanda's commitment to advancing clinical trials and obtaining regulatory approvals, aiming to maintain momentum in the psychiatric medication landscape. The company remains focused on the market's vast potential estimated to be approximately $20 billion, enhancing its competitive stance within the antipsychotic category.
Conclusion
With a promising outlook for 2026, Vanda Pharmaceuticals is not only building on a strong foundation established through its financial results but is also actively working on expanding its treatment portfolio. Through innovation and strategic focus, Vanda is positioned for success in addressing significant patient needs and enhancing shareholder value.
Frequently Asked Questions
What were Vanda Pharmaceuticals' total revenues in 2025?
Total revenues for Vanda Pharmaceuticals in 2025 were $216.1 million, reflecting a 9% increase over the previous year.
How much did Fanapt's net product sales increase in 2025?
Fanapt's net product sales increased by 24% to $117.3 million in 2025 compared to 2024.
What significant FDA approval did Vanda recently receive?
Vanda received FDA approval for NEREUS™, marking a significant milestone as the first new oral therapy for motion-induced vomiting in over 40 years.
What is Vanda's financial guidance for 2026?
Vanda expects total revenues in the range of $230 million to $260 million for 2026.
Who is the CEO of Vanda Pharmaceuticals?
Mihael H. Polymeropoulos, M.D., is the President, CEO and Chairman of the Board at Vanda Pharmaceuticals.
